Application
Time-resolved fluorescene (TRF) reagent for assays of the cytotoxic activity of immune effector cells against tumor cells (including ones which are opsonized with antibodies).
Advantages
- Non-RI small molecule
- Lower background level
- Shorter measurement time
Background and Technology
A novel non-RI reagent for TRF with highly maximum release and lower spontaneous release from cell. This molecule is more potent than well-known chelating lanthanide-labeled TRF reagent; DELFIA® (Perkin Elmer).
When the tumor cells are pretreated with this novel pro-chelate-forming compound, its hydrolyzate is released upon disruption of the tumor cell membrane during the cellular killing. Upon addition of Europium (Eu), the cellular cytotoxicity can be determined by TRF within very short measuring time (30–40 min.).
Publication
Sakai Y., Tanaka Y., et al. ChemMedChem. 2017; 12(23): 2006-2013.
doi: 10.1002/cmdc.201700626.
Patents
Issued in Japan (JP 6501271), Europe (EP 3127899) and the United States (US 10175229).
Notes:
Although the Japanese patent has been licensed only for research use and the product is now commercially available, it is still available for the clinical use.
Researchers
Dr. Yoshimasa TANAKA, et al. (Professor, Nagasaki University, Japan)
Expectations
We are looking for both biotech companies to develop this technology and sell products for research use, and pharmaceutical companies to use for the evaluation for their clinical purpose (i.e. for cell therapy products).
JT-00546